Glycans associated with biopharmaceutical drugs play crucial roles in drug safety and efficacy,and therefore,their reliable detection and quantification is essential.Our study introduces a multi-level quantification a...Glycans associated with biopharmaceutical drugs play crucial roles in drug safety and efficacy,and therefore,their reliable detection and quantification is essential.Our study introduces a multi-level quantification approach for glycosylation analysis in monoclonal antibodies(mAbs),focusing on minor abundant glycovariants.Mass spectrometric data is evaluated mainly employing open-source software tools.Released N-glycan and glycopeptide data form the basis for integrating information across different structural levels up to intact glycoproteins.Comprehensive comparison showed that indeed,variations across structural levels were observed especially for minor abundant species.Utilizing modification finder(MoFi),a tool for annotating mass spectra of intact proteins,we quantify isobaric glycosylation variants at the intact protein level.Our workflow's utility is demonstrated on NISTmAb,rituximab and adalimumab,profiling their minor abundant variants for the first time across diverse structural levels.This study enhances understanding and accessibility in glycosylation analysis,spotlighting minor abundant glycovariants in therapeutic antibodies.展开更多
文摘Glycans associated with biopharmaceutical drugs play crucial roles in drug safety and efficacy,and therefore,their reliable detection and quantification is essential.Our study introduces a multi-level quantification approach for glycosylation analysis in monoclonal antibodies(mAbs),focusing on minor abundant glycovariants.Mass spectrometric data is evaluated mainly employing open-source software tools.Released N-glycan and glycopeptide data form the basis for integrating information across different structural levels up to intact glycoproteins.Comprehensive comparison showed that indeed,variations across structural levels were observed especially for minor abundant species.Utilizing modification finder(MoFi),a tool for annotating mass spectra of intact proteins,we quantify isobaric glycosylation variants at the intact protein level.Our workflow's utility is demonstrated on NISTmAb,rituximab and adalimumab,profiling their minor abundant variants for the first time across diverse structural levels.This study enhances understanding and accessibility in glycosylation analysis,spotlighting minor abundant glycovariants in therapeutic antibodies.
